Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: UK-500,001

Study type: Interventional

Funder types: Industry

Identifiers

NCT00263874

A5641009

Details and patient eligibility

About

This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate-severe COPD (Global inititiative for chronic Obstructive Lung Disease, GOLD, 2003 definition)
• Smoking history of at least 10 pack-years

Exclusion criteria

• Any significant co-morbid disease
• Use of any maintenance therapy except short acting bronchodilators

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind